Cognitive Behavioral Therapy After Esketamine for Depression with Suicidal Ideation
(ENDURE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether adding Cognitive Behavioral Therapy (CBT) after esketamine treatment can better assist individuals with Major Depression and Suicidal Thoughts. All participants will initially receive esketamine, a medication for severe depression. Subsequently, some participants will also undergo CBT, a type of talk therapy, while others will receive standard care without formal CBT. Suitable candidates have major depressive disorder, were recently hospitalized for suicidal thoughts or attempts, and have a doctor's recommendation for esketamine treatment. As an unphased trial, this study provides participants the chance to contribute to innovative research that could enhance future treatment options.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that cognitive behavioral therapy (CBT) is generally well-received by patients. It helps manage mental health issues like depression and anxiety by changing negative thoughts and behaviors.
Although CBT is a common and safe treatment, discussing any concerns with a healthcare provider is important. This trial will use CBT alongside esketamine, a medication for depression. Both treatments are considered safe, but individual experiences can differ. Always consult a medical professional to determine the best options.12345Why are researchers excited about this trial?
Researchers are excited about using Cognitive Behavioral Therapy (CBT) after esketamine treatment for depression with suicidal ideation because it offers a unique combination of therapies. Unlike standard treatments like medication and psychotherapy, CBT is structured and goal-oriented, focusing on changing thought patterns and behaviors. This trial is exploring how CBT, when combined with the fast-acting effects of esketamine, could potentially provide both immediate relief and long-term benefits. This approach could be especially beneficial in managing suicidal thoughts more effectively than traditional treatments alone.
What evidence suggests that this trial's treatments could be effective for Major Depression with Suicidal Ideation?
Research has shown that Cognitive Behavioral Therapy (CBT), which participants in this trial may receive, effectively treats depression. It helps individuals identify and change negative thoughts and behaviors. Studies have found that CBT reduces depression symptoms by teaching coping strategies. This practical therapy focuses on changing behavior through methods like positive reinforcement and improved communication. By addressing irrational fears and encouraging positive actions, CBT enables individuals to manage their depression more effectively.678910
Who Is on the Research Team?
Samuel T Wilkinson, MD
Principal Investigator
Yale University
Are You a Good Fit for This Trial?
Adults aged 18-65 with major depression and suicidal thoughts, who are recommended for esketamine treatment, can join. They must be willing to use contraception and follow the trial procedures. Excluded are those pregnant or breastfeeding, with certain cognitive disorders, no response to prior ketamine treatments, substance abuse issues within the last 6 months, or other serious medical/psychiatric conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive esketamine for treatment of Major Depression with Suicidal Ideation, followed by randomization to CBT or TAU
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cognitive Behavioral Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator